ArticleBMC neurology2025
Serum transferrin as a potential marker for prediction of prognosis for sudden sensorineural hearing loss: a prospective study.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multimodal biomarkers in idiopathic sudden sensorineural hearing loss: integrating immune, vascular, and metabolic perspectives for precision medicine.Frontiers in immunology · 2026Review
- Stroke thrombolysis for patients with intracranial aneurysms: a nationwide cohort study.Journal of neurology · 2025Article
- Construction and efficacy evaluation of a prognostic assessment model for corticosteroid treatment in patients with sudden sensorineural hearing loss based on lipid metabolism profile.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveClinically significant prognostic indicators have not been identified for sudden sensorineural hearing loss (SSNHL). Consequently, this research aimed to evaluate the effectiveness of iron parameters in predicting prognostic outcomes for patients with SSNHL.
methodsNinety-one individuals with SSNHL were prospectively enrolled and received steroid treatment at a dosage of 1 mg/kg/day for two weeks. Baseline characteristics and iron parameters were collected from participants. Afterward, the pre-and post-treatment hearing of the enrolled patients was compared. The effective group, defined as those with a pure tone audiometry (PTA) improvement of impaired frequencies of ≥ 15 dB or restoration to normal/ unaffected ear levels。.
resultsIn the entire cohort, the effective group exhibited a significantly younger age (p = 0.005) and baseline hearing level as well as transferrin saturation (p = 0.036) and higher transferrin levels (p = 0.002) in comparison to the ineffective group. Multivariate analysis identified age (OR, 0.931; 95% CI, 0.889-0.976; p = 0.003), the baseline hearing level (OR, 0.928; 95% CI, 0.894-0.964; p<0.001) and transferrin level (OR, 9.15; 95% CI, 1.838-45.555; p = 0.007) as independent predictors of treatment outcome.
conclusionsHigher transferrin levels were associated with an optimal outcome for SSNHL, however further research is needed to understand the mechanisms underlying this effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.